Fosmanogepix is a small molecule commercialized by Pfizer, with a leading Phase I program in Coccidioidomycosis. According to Globaldata, it is involved in 14 clinical trials, of which 11 were completed, 1 is ongoing, 1 is planned, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Fosmanogepix’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Fosmanogepix is expected to reach an annual total of $7 mn by 2035 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
APX-001 is under development for the treatment of drug-resistant candidiasis, cryptococcosis, coccidioidomycosis, scedosporiosis, fusariosis, mucormycosis and rare moulds. The drug candidate is administered through the intravenous and oral route. The drug candidate targets GWT1 and is developed based on a platform approach to improving small molecule drugs by the addition of a second small molecule to an existing drug.
It was under development for the treatment of candidiasis and invasive aspergillosis.
Pfizer discovers, develops, manufactures, and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, women’s health, cancer, inflammation, immune disorders, and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, individual provider offices, clinics, government agencies and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa, and the Middle East. Pfizer is headquartered in New York, the US.
The company reported revenues of (US Dollars) US$100,330 million for the fiscal year ended December 2022 (FY2022), an increase of 23.4% over FY2021. In FY2022, the company’s operating margin was 36.4%, compared to an operating margin of 29.1% in FY2021. In FY2022, the company recorded a net margin of 31.3%, compared to a net margin of 27% in FY2021. The company reported revenues of US$18,282 million for the first quarter ended March 2023, a decrease of 24.7% over the previous quarter.
For a complete picture of Fosmanogepix’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.